Virus inactivation in albumin by a combination of alkali conditions and high temperature

Biologicals

Volumn 39, Issue 2, 2011, Pages 67-72

  Roberts, Peter L ^a   More, John ^a   Rott, Jackie ^a   Lewin, David ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Albumin; Alkali pH; Non enveloped viruses; Pasteurisation; Virus inactivation

Indexed keywords

HUMAN ALBUMIN; PHENOLSULFONPHTHALEIN; UNCLASSIFIED DRUG; ZENALB;

ALKALINITY; ARTICLE; BOCAVIRUS; CONTROLLED STUDY; DRUG SAFETY; FELINE PANLEUKOPENIA VIRUS; HEPATITIS A VIRUS; HIGH TEMPERATURE; LIGAND BINDING; NONHUMAN; PASTEURIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN STABILITY; SIMIAN VIRUS 40; VIRUS ENVELOPE; VIRUS INACTIVATION;

ALBUMINS; ALKALIES; ANIMALS; BOCAVIRUS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; HEPATITIS A VIRUS; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; PARVOVIRUS, CANINE; PROTEIN STABILITY; SIMIAN VIRUS 40; VERO CELLS; VIRUS INACTIVATION;

HEPATITIS A VIRUS;

EID: 79952539095     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.01.001     Document Type: Article

References (29)

1. Burnouf T., Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000, 14:94-110.
2. Roberts P.L. Virus safety of plasma products. Rev Med Virol 1996, 6:25-38.
3. Committee for Proprietary Medicinal Products. European medicines evaluation agency: note for guidance on plasma-derived medicinal products. CPMP/BWP/269/95 rev 3; 2001.
4. Horowitz B., Prince A.M., Horowitz M.S. Watklevicz. Virus safety of solvent-detergent treated blood products. Dev Biol Stand 1993, vol. 81:147-161. Karger, Basel. F. Brown (Ed.).
5. Prowse C., Follett E., Prince A. Hepatitis A virus transmission by blood products. Vox Sang 1994, 67(S1):1-87.
6. Laub R., Strengers P. Parvoviruses and blood products. Pathol Biol (Paris) 2002, 50:339-348.
7. Prowse C., Ludlam C.A., Yap P.L. Human parvovirus B19 and blood products. Vox Sang 1997, 72:1-10.
8. Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., Ball L.A. Virus taxonomy. Classification and nomenclature of viruses. Eighth report of the international committee on the taxonomy of viruses 2005, Elsevier Academic Press, London.
9. Willkommen H., Schmidt I., Lower J. Safety issues for plasma derivatives and benefit from NAT testing. Biologicals 1999, 27:325-331.
10. Brooker M. Registry of clotting factor concentrates 2008, World Federation of Haemophilia.
11. Kempf C., Stucki M., Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulin. Biologicals 2007, 35:35-42.
12. Gellis S.S., Neefe J.R., Stokes J., Strong L.E., Janeway C.A., Scatchard G., et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation, XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of Norman human serum albumin by means of heat. J Clin Invest 1948, 27:239-244.
13. Edsall J.T. Stabilization of serum albumin to heat, and inactivation of the hepatitis virus. Vox Sang 1984, 46:338-340.
14. Murphy P., Nowak T., Lemon S.M., Hilfenhaus J. Inactivation of hepatitis A by heat treatment in acqueous solution. J Med Virol 1993, 41:61-64.
15. Shimasaki N, Kiyohara T, Totsuka A, Nojima K, Okada Y, Yamaguchi K et al. Inactivation of hepatitis A virus by heat and high hydrostatic pressure: variation among laboratory strains. Vox Sang 2009;96:14-19.
16. Barrett P.N., Meyer H., Wachtel I., Eibl J., Dorner F. Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a TCID50 assay. J Med Virol 1996, 49:1-6.
17. Terpstra F.G., Kleijn M., Koenderman A.H., Over J., van Engelenburg F.A., Schuitemaker H., et al. Viral safety of C1-inhibitor NF. Biologicals 2007, 35:173-181.
18. Yunok M., Tsujikawa M., Urayama T., Sasaki Y., Morita M., Tanaka H., et al. Heat sensitivity of human parvovirus B19. Vox Sang 2003, 84:164-169.
19. Use of sodium hydroxide for cleaning and sanitizing chromatography media and systems. Process Chromatogr 2001, Amersham Biosciences, Application note.
20. Kistler P., Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962, 7:414-424.
21. Rodkey F.L. Binding of phenol red by human serum albumin. Arch Biochem Biophys 1961, 94:526-531.
22. Burnouf T., Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003, 9:24-37.
23. MacLeod A.J. UV-C irradiation of human albumin solution on manufacturing scale. Dev Biol Basel 2004, 118:139-147.
24. Johnston A., Uren E., Johnstone D., Wu J. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies. Biologicals 2003, 31:213-221.
25. European pharmacopeia 2009, Council of Europe. 6th ed.
26. Curry S. Beyond expansion: structural studies on the transport roles of human serum albumin. Vox Sang 2002, 83(Suppl. 1):315-319.
27. Morgenthaler J.J. Effect of ethanol on viruses. Curr Stud Hematol Blood Transfus 1989, 56:109-121.
28. Morgenthaler J.J., Omar A. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulin by cold ethanol fractionation. Dev Biol Stand 1993, 81:185-190.
29. Kragh-Hansen U. Structural and ligand binding properties of human serum albumin. Dan Med Bull 1990, 37:57-84.